Results 41 to 50 of about 18,764 (290)

YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells [PDF]

, 2013
Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence.
Beier, Dagmar, Girbinger, Vroni, Holm, Per Sonne, Lage, Hermann, Mantwill, Klaus, Mittelbronn, Michel Guy André, Naumann, Ulrike, Schlegel, Jürgen, Seznec, Janina, Surowiak, Pawel   +9 more
core   +1 more source

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

Nature Communications, 2023
IDH1 mutations frequently occur early in human glioma. While IDH1 mutation has been shown to promote gliomagenesis via DNA and histone methylation, little is known regarding its regulation in antiviral immunity.
Xueqin Chen, Jun Liu, Yuqin Li, Yuequan Zeng, Fang Wang, Zexiong Cheng, Hao Duan, Guopeng Pan, Shangqi Yang, Yuling Chen, Qing Li, Xi Shen, Ying Li, Zixi Qin, Jiahong Chen, Youwei Huang, Xiangyu Wang, Yuli Lu, Minfeng Shu, Yubo Zhang, Guocai Wang, Kai Li, Xi Lin, Fan Xing, Haipeng Zhang   +24 more
semanticscholar   +1 more source

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs [PDF]

, 2013
Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses that propagate only in actively dividing tumor cells but not in normal cells and, as a result, destroy the tumor cells by ...
Braidwood, L., Conner, J., Graham, A., Graham, S.V.   +3 more
core   +1 more source

Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression

Immunotherapy Advances, 2023
Summary Cancer therapeutics can lead to immune equilibrium in which the immune response controls tumor cell expansion without fully eliminating the cancer.
Michael J. Walsh, Lestat R. Ali, P. Lenehan, Courtney T S Kureshi, R. Kureshi, M. Dougan, D. Knipe, S. Dougan   +7 more
semanticscholar   +1 more source

Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways

Vaccines, 2020
Myxoma virus (MYXV) is the prototypic member of the Leporipoxvirus genus of the Poxviridae family of viruses. In nature, MYXV is highly restricted to leporids and causes a lethal disease called myxomatosis only in European rabbits (Oryctologous cuniculus)
Masmudur M. Rahman, Grant McFadden
doaj   +1 more source

Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration

Theranostics, 2023
Rationale: Immuno-virotherapy has emerged as a promising approach for cancer treatment, as it directly and cytotoxically eliminates tumors with systemic immune stimulation.
Yuzhi Liang, Bing Wang, Qingjing Chen, Xingyue Fu, Chenwei Jiang, Zhiwen Lin, Q. Zhuang, Yongyi Zeng, Xiaolong Liu, Da Zhang   +9 more
semanticscholar   +1 more source

Autophagy gene activity may act as a key factor for sensitivity of tumor cells to oncolytic vesicular stomatitis virus [PDF]

, 2016
Background: Beclin1 is an important, primary molecule for autophagy. Objectives: It is suggested that the control of the autophagy path increases the sensitivity of tumor cells to VSV.
Arefian, E., Bamdad, T., Nabizadeh, A., Razavi Nikoo, S.H.   +3 more
core   +2 more sources

Recombinant Myxoma Virus-Derived Immune Modulator M-T7 Accelerates Cutaneous Wound Healing and Improves Tissue Remodeling

Pharmaceutics, 2020
Complex dermal wounds represent major medical and financial burdens, especially in the context of comorbidities such as diabetes, infection and advanced age.
Jordan R. Yaron, Liqiang Zhang, Qiuyun Guo, Enkidia A. Awo, Michelle Burgin, Lauren N. Schutz, Nathan Zhang, Jacquelyn Kilbourne, Juliane Daggett-Vondras, Kenneth M. Lowe, Alexandra R. Lucas   +10 more
doaj   +1 more source

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

Frontiers in Immunology, 2021
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them.
Victor Cervera-Carrascon, Victor Cervera-Carrascon, Dafne C. A. Quixabeira, Joao M. Santos, Joao M. Santos, Riikka Havunen, Riikka Havunen, Ioanna Milenova, Ioanna Milenova, Jan Verhoeff, Camilla Heiniö, Sadia Zafar, Juan J. Garcia-Vallejo, Victor W. van Beusechem, Tanja D. de Gruijl, Aino Kalervo, Suvi Sorsa, Anna Kanerva, Anna Kanerva, Akseli Hemminki, Akseli Hemminki, Akseli Hemminki   +21 more
doaj   +1 more source

Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs [PDF]

, 2017
BACKGROUND: Radiogenetic therapy is a novel approach in the treatment of cancer, which employs genetic modification to alter the sensitivity of tumor cells to the effect of applied radiation.
Arafat WO, Arafat WO, Datta R, Deb P, Fiveash JB, Hsu H, Kanzawa T, Kawakami Y, Kufe D, Nandi S, Nenoi M, Nieder C, Pinsker M, Rosenfeld ME, Sonabend AM, Tsai‐Morris CH, Weichselbaum RR   +16 more
core   +2 more sources